<DOC>
	<DOC>NCT02614547</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female subjects diagnosed with severe postpartum depression</brief_summary>
	<brief_title>A Study to Evaluate SAGE-547 in Patients With Severe Postpartum Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression, Postpartum</mesh_term>
	<criteria>Key Subject either must have ceased lactating at Screening; or if still lactating at Screening, must have already fully and permanently weaned their infant(s) from breastmilk; or if still actively breastfeeding at Screening, must agree to cease giving breastmilk to their infant(s) prior to receiving study drug. Subject has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSMIV Axis I Disorders (SCIDI) Subject is â‰¤ six months postpartum Subject must be amenable to IV therapy Key Active psychosis Attempted suicide associated with index case of postpartum depression Medical history of seizures Medical history of bipolar disorder Note: suicidal ideation is not an exclusion. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>